Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Allergan, Brent Saunders
Allergan CEO Saunders lines up for $39M payout after AbbVie buy
Wednesday, August 14, 2019
If Allergan CEO Brent Saunders is let go after AbbVie’s $63 billion takeover of the California company goes through, he'll net a cool $38.7 million.
AbbVie was Allergan's only suitor in $63B megatakeover: proxy
Tuesday, August 13, 2019
AbbVie and Allergan’s $63 billion merger was a shock to the industry, but only talking to each other kept negotiations between CEOs under wraps.
Analysts rip into AbbVie's $63B Allergan buy
Wednesday, June 26, 2019
AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.
AbbVie bails out struggling Allergan with $63B deal
Tuesday, June 25, 2019
Allergan investors have been pushing for action from management, and AbbVie has been hunting for new revenue streams. Now, they're set to combine.
Allergan preparing to split after years of turmoil: analyst
Wednesday, June 19, 2019
Allergan's shares have significantly fallen from their highs in 2015, but now the company is ready to make a big move, one analyst writes.
Evolus' promotional Cancun bash sparks controversy
Thursday, May 16, 2019
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.
Under investor fire, Allergan's eyeing 'all options,' CEO says
Tuesday, May 7, 2019
Shareholders let Allergan's Brent Saunders keep both his chairman and CEO titles, but that doesn't mean he's not acting on their criticisms.
Allergan CEO Saunders gets to keep chairmanship
Wednesday, May 1, 2019
Appaloosa's attempt to split Allergan's CEO and chair positions came up short at an investor meeting Wednesday.
Proxy advisers back Allergan in leadership fight
Monday, April 15, 2019
Allergan has been warring with investors pushing for a change to the company's leadership structure, but leading proxy adviser firms aren't on board.